Leerink Partners analyst Marc Goodman has maintained their bullish stance on NBIX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman has given his Buy rating due to a combination of factors that highlight Neurocrine’s promising financial outlook. The strong performance of Crenessity, with sales projections increasing significantly from approximately $100 million to $235 million for 2025, has been a key driver in this positive assessment. Despite a slight reduction in Ingrezza’s sales growth guidance for 2025, the overall print was considered strong, reinforcing confidence in the company’s diversified portfolio.
Additionally, Ingrezza’s sales figures exceeded expectations, with a record number of patient starts in the second quarter of 2025. Management’s belief in gaining market share, despite competitive pressures, further supports the optimistic outlook. The narrowing of Ingrezza’s 2025 sales guidance to $2.5-2.55 billion, along with strategic adjustments for Medicare formulary coverage, indicates a robust approach to navigating market challenges. Overall, these factors contribute to a favorable view of Neurocrine’s stock potential.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.
NBIX’s price has also changed moderately for the past six months – from $153.290 to $136.760, which is a -10.78% drop .